Table 3.

Adverse events and complications during follow-up

Adverse EventCyclophosphamide
(n=91)Other Immunosuppression
(n=33)Conservative Treatment
(n=130)
Serious adverse event35 (38)11 (33)12 (9)
Resulting in (prolongation of) hospitalization13 (14)3 (9)2 (2)
Leukopenia35 (38)8 (24)2 (2)
Thrombopenia7 (8)2 (6)0
Liver enzyme abnormalities7 (8)00
Hyperglycemia10 (11)5 (15)1 (1)
Infection30 (33)11 (33)1 (1)
Hematuria/cystitis1 (1)00
Cardiovascular/thrombotic events18 (20)7 (21)8 (6)
Subfertility000
Osteonecrosis000
Malignancy14 (15)2 (6)4 (3)
  • Serious adverse events have been defined according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice guidelines. Values are n (%).